Skip to main content
SpringerLink
Log in

Measles–Mumps–Rubella Vaccine

  • Chapter
  • First Online:
Pediatric Vaccines and Vaccinations

  • 1416 Accesses

Abstract

The measles–mumps–rubella (MMR) vaccine is currently the exclusive tool for the prevention of measles, mumps, and rubella in Europe. The description below of single measles, mumps, and rubella vaccines is given for historical reasons and for the characterization of their properties as components of the MMR vaccine. Previous immunization programs with single vaccines, usually given as a single dose, were generally less effective than the current MMR immunization programs in early childhood, with the vaccine given in two doses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Further Reading

  • Bolotovski V, et al. Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. Int J Epidemiol. 1994;23(5):1069–77.

    Article  CAS  PubMed  Google Scholar 

  • Bottiger M, et al. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps and rubella. BMJ. 1987;295:1264–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davis NF, et al. The increasing incidence of mumps orchitis: a comprehensive review. BJU Int. 2010;105(8):1060–5.

    Article  PubMed  Google Scholar 

  • Edmunds WJ, et al. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect. 2000;125(3):635–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Enders J. Measles virus. Historical review, isolation, and behavior in various systems. Am J Dis Child. 1962;103:282–7.

    Article  CAS  PubMed  Google Scholar 

  • Enders JF, Peebles TC. Propagation in tissue cultures of cytopathic agents from patients with measles. Proc Soc Exp Biol Med. 1954;86:277–86.

    Article  CAS  PubMed  Google Scholar 

  • Garenne M, et al. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet. 1991;338(8772):903–7.

    Article  CAS  PubMed  Google Scholar 

  • Ikić DM. Edmonston-Zagreb strain of measles vaccine: epidemiologic evaluation in Yugoslavia. Rev Infect Dis. 1983;5(3):558– 63.

    Article  PubMed  Google Scholar 

  • Immunization Safety Review Committee, Immunization safety review. Vaccines and autism. 2004, Washington, DC: National Academies Press. p. 214.

    Google Scholar 

  • Klein N, Fireman B, Yih K, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010;126(1):e1–8.

    Google Scholar 

  • Lievano F, et al. Measles, mumps, and rubella virus vaccine (M–M–R™II): a review of 32 years of clinical and postmarketing experience. Vaccine. 2012;30(48):6918–26.

    Article  PubMed  Google Scholar 

  • Mercader S, Garcia P, Bellini WJ. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vaccine Immunol 2012;19:1810–1817.

    Google Scholar 

  • Peltola H, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 1994;331(21):1397–402.

    Article  CAS  PubMed  Google Scholar 

  • Peltola H, et al. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis. 2008;8:796–803.

    Article  PubMed  Google Scholar 

  • Plotkin SA. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis. 2006;43(Suppl 3):S164–8.

    Article  PubMed  Google Scholar 

  • Plotkin S, Mortimer E. Vaccines. 2nd ed. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: W.B. Saunders Company; 1994.

    Google Scholar 

  • Plotkin SA, et al. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child. 1969;118:178–85.

    CAS  PubMed  Google Scholar 

  • Stratton K, et al. Measles-mumps-rubella vaccine and autism. Immunization Safety Review. National Academy Press, Washington, DC; 2001.

    Google Scholar 

  • Usonis V, et al. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Infection. 1998;26(4):222–6.

    Article  CAS  PubMed  Google Scholar 

  • Usonis V, et al. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J. 1999;18(1):42–8.

    Article  CAS  PubMed  Google Scholar 

  • Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007;26(7):632–8.

    Article  PubMed  Google Scholar 

  • Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637–41.

    Google Scholar 

  • WHO Euro. Measles and rubella elimination. package for accelerated action 2013–2015.

    Google Scholar 

  • WHO Position Paper. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51–60.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Tampere, Vaccine Research Center, Tampere, Finland

    Timo Vesikari

  2. Vilnius University Faculty of Medicine, Clinic of Children Diseases, Vilnius, Lithuania

    Vytautas Usonis

Authors
  1. Timo Vesikari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vytautas Usonis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timo Vesikari .

Editor information

Editors and Affiliations

  1. Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland

    Timo Vesikari

  2. Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Antwerpen, Belgium

    Pierre Van Damme

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Vesikari, T., Usonis, V. (2017). Measles–Mumps–Rubella Vaccine. In: Vesikari, T., Van Damme, P. (eds) Pediatric Vaccines and Vaccinations. Springer, Cham. https://doi.org/10.1007/978-3-319-59952-6_9

Download citation

Publish with us

Policies and ethics

Search

Navigation